CVS Health to Produce Lower-Cost ‘Biosimilar’ Medicines
CVS Health is set to establish Cordavis, a subsidiary unit aimed at partnering with pharmaceutical companies to develop biosimilar products, which are essentially replicas of already approved drugs. The primary objective of this unit is to introduce FDA-approved biosimilar products to the U.S. market, potentially revolutionizing the way consumers purchase medications by fostering competition and reducing prices. This subsidiary does not reinvent the wheel with new drugs. All manufactured biosimilar products are very similar to an already approved biologic drug, but are tested and approved to ensure that they are…
Read More